Bicyclic compounds as Pim inhibitors

US9090593B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Hui-Ling Wang · Thousand Oaks, US
• Kaustav Biswas · Thousand Oaks, US
• Victor J. Cee · Thousand Oaks, US
• Frank Chavez · San Diego, US
• Bradley J. Herberich · Newbury Park, US
• Claire L. M. Jackson · Thousand Oaks, US
• Brian Alan LANMAN · Calabasas, US
• Matthew Lee · Calabasas, US
• Thomas Nixey · Newbury Park, US
• Liping H. Pettus · Thousand Oaks, US
• Anthony B. Reed · Newbury Park, US
• Robert M. Rzasa · Ventura, US
• Shannon Rumfelt · Camarillo, US
• Andrew Tasker · Simi Valley, US
• Bin Wu · Thousand Oaks, US
• Ryan Wurz · Newbury Park, US

Key dates

• Filing date: Dec 7, 2011
• Grant date: Jul 28, 2015
• Expiry date: Dec 7, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to bicyclic compounds of formula (1′), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.